Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. more
Time Frame | KRBP | Sector | S&P500 |
---|---|---|---|
1-Week Return | - | -2.82% | 0.15% |
1-Month Return | -2.06% | -4.22% | 1.78% |
3-Month Return | -52.85% | -9.52% | 8.7% |
6-Month Return | -60.42% | -3.45% | 12.24% |
1-Year Return | 427.78% | 5.62% | 30.9% |
3-Year Return | -98.27% | 3.8% | 30.19% |
5-Year Return | -99.72% | 39.68% | 91.72% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 200.00K | 469.80K | 2.07M | 2.80M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":7.15,"profit":true},{"date":"2021-12-31","value":16.8,"profit":true},{"date":"2022-12-31","value":73.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | (200.00K) | (469.80K) | (2.07M) | (2.80M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-20000000,"profit":false},{"date":"2021-12-31","value":-46980000,"profit":false},{"date":"2022-12-31","value":-206760000,"profit":false},{"date":"2023-12-31","value":-279590000,"profit":false}] |
Gross Margin | - | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 3.71M | 19.20M | 25.31M | 31.11M | 19.94M | [{"date":"2019-12-31","value":11.91,"profit":true},{"date":"2020-12-31","value":61.7,"profit":true},{"date":"2021-12-31","value":81.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":64.08,"profit":true}] |
Operating Income | (3.71M) | (19.20M) | (25.74M) | (31.11M) | (19.94M) | [{"date":"2019-12-31","value":-370540000,"profit":false},{"date":"2020-12-31","value":-1919690000,"profit":false},{"date":"2021-12-31","value":-2573570000,"profit":false},{"date":"2022-12-31","value":-3111430000,"profit":false},{"date":"2023-12-31","value":-1993930000,"profit":false}] |
Total Non-Operating Income/Expense | (45.00K) | (6.60K) | 134.80K | (3.78M) | (2.86M) | [{"date":"2019-12-31","value":-33.38,"profit":false},{"date":"2020-12-31","value":-4.9,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2806.53,"profit":false},{"date":"2023-12-31","value":-2123.29,"profit":false}] |
Pre-Tax Income | (3.73M) | (19.20M) | (25.59M) | (34.73M) | (20.95M) | [{"date":"2019-12-31","value":-372790000,"profit":false},{"date":"2020-12-31","value":-1920020000,"profit":false},{"date":"2021-12-31","value":-2558870000,"profit":false},{"date":"2022-12-31","value":-3473100000,"profit":false},{"date":"2023-12-31","value":-2094930000,"profit":false}] |
Income Taxes | 22.50K | 3.30K | 65.60K | 3.45M | 344.70K | [{"date":"2019-12-31","value":0.65,"profit":true},{"date":"2020-12-31","value":0.1,"profit":true},{"date":"2021-12-31","value":1.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.99,"profit":true}] |
Income After Taxes | (3.75M) | (19.20M) | (25.65M) | (38.18M) | (21.29M) | [{"date":"2019-12-31","value":-375040000,"profit":false},{"date":"2020-12-31","value":-1920350000,"profit":false},{"date":"2021-12-31","value":-2565430000,"profit":false},{"date":"2022-12-31","value":-3818120000,"profit":false},{"date":"2023-12-31","value":-2129400000,"profit":false}] |
Income From Continuous Operations | (3.73M) | (19.20M) | (25.59M) | (34.73M) | (20.95M) | [{"date":"2019-12-31","value":-372790000,"profit":false},{"date":"2020-12-31","value":-1920020000,"profit":false},{"date":"2021-12-31","value":-2558870000,"profit":false},{"date":"2022-12-31","value":-3473100000,"profit":false},{"date":"2023-12-31","value":-2094930000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.75M) | (19.20M) | (25.65M) | (38.18M) | (21.29M) | [{"date":"2019-12-31","value":-375040000,"profit":false},{"date":"2020-12-31","value":-1920350000,"profit":false},{"date":"2021-12-31","value":-2565430000,"profit":false},{"date":"2022-12-31","value":-3818120000,"profit":false},{"date":"2023-12-31","value":-2129400000,"profit":false}] |
EPS (Diluted) | (2.03) | (5.27) | (13.61) | (39.75) | - | [{"date":"2019-12-31","value":-202.86,"profit":false},{"date":"2020-12-31","value":-526.89,"profit":false},{"date":"2021-12-31","value":-1361,"profit":false},{"date":"2022-12-31","value":-3975,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
KRBP | |
---|---|
Cash Ratio | 0.15 |
Current Ratio | 0.22 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KRBP | |
---|---|
ROA (LTM) | -119.42% |
ROE (LTM) | -1129.81% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KRBP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.91 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KRBP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 11.55 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Kiromic Biopharma Inc (KRBP) share price today is $0.95
Yes, Indians can buy shares of Kiromic Biopharma Inc (KRBP) on Vested. To buy Kiromic Biopharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KRBP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kiromic Biopharma Inc (KRBP) via the Vested app. You can start investing in Kiromic Biopharma Inc (KRBP) with a minimum investment of $1.
You can invest in shares of Kiromic Biopharma Inc (KRBP) via Vested in three simple steps:
The 52-week high price of Kiromic Biopharma Inc (KRBP) is $3.78. The 52-week low price of Kiromic Biopharma Inc (KRBP) is $0.28.
The price-to-earnings (P/E) ratio of Kiromic Biopharma Inc (KRBP) is
The price-to-book (P/B) ratio of Kiromic Biopharma Inc (KRBP) is 11.55
The dividend yield of Kiromic Biopharma Inc (KRBP) is 0.00%
The market capitalization of Kiromic Biopharma Inc (KRBP) is $1.69M
The stock symbol (or ticker) of Kiromic Biopharma Inc is KRBP